Arcutis Biotherapeutics, Inc. (ARQT) FinancialsARQTFinancialArcutis Biotherapeutics, Inc.

Evaluating the bottom line, Arcutis Biotherapeutics, Inc. maintains a gross margin of 91.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.65%, while the net margin is 11.56%. These profitability ratios, combined with a Return on Equity (ROE) of 15.86%, provide a clear picture of how effectively ARQT converts its operational activities into shareholder value.

In the context of the broader market, ARQT competes directly with industry leaders such as ALMS and NAMS. With a market capitalization of $3.29B, it holds a leading position in the sector. When comparing efficiency, ARQT's gross margin of 91.58% stands against ALMS's 100.00% and NAMS's 100.00%. Such benchmarking helps identify whether Arcutis Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a profit of $15.01 million for Q2 2026, with revenues increasing to $129.86 million, a significant rise from $81.50 million in the previous year, indicating strong growth driven by ZORYVE demand.